Kyowa Kirin stock
Price history
+4.06% over the period1 year: from ¥2,499.00 (November 17, 2025) to ¥2,600.50 (November 16, 2026), +4.06%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | ¥2,600.50 |
| October 30, 2026 | ¥2,464.00 |
| September 30, 2026 | ¥2,280.00 |
| August 31, 2026 | ¥2,628.00 |
| July 31, 2026 | ¥2,554.50 |
| June 30, 2026 | ¥2,587.00 |
| May 29, 2026 | ¥2,505.00 |
| April 30, 2026 | ¥2,362.00 |
| March 31, 2026 | ¥2,578.00 |
| February 27, 2026 | ¥2,885.00 |
| January 30, 2026 | ¥2,504.50 |
| December 30, 2025 | ¥2,527.00 |
| November 28, 2025 | ¥2,630.50 |
| November 17, 2025 | ¥2,499.00 |
At a glance
The company
Develops and markets pharmaceutical products for oncology, dermatology, ophthalmology and rare diseases
Latest results
Quarter to September 30, 2026 · EPS ¥40.22 (estimate ¥38.01)
Next event
Dividend
TickerLandia's take on Kyowa Kirin
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 20 vs a median of 29 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 17 vs 28 (−41%) in a group of 11.
- Strong point: Financial strength (83/100 in its group). Weak point: Growth (48/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.70% from the 52-week high
Analysts · 11 analysts
Average target¥2,263.64−12.95% vs. price
Buy 1 · Hold 4 · Sell 6 · Sell
TickerLandia Fingerprint: Kyowa Kirin
Compared with similar companies: very high financial strength.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricelow27
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 8.52 18 P/E (trailing 12 months) 16.6 19 Forward P/E 18.6 46 Price/sales 2.54 38 Price/book 1.49 14 Profitabilityaverage52
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 74.7% 68 Operating margin 21.8% 58 ROE 9.8% 29 ROA 5.5% 42 Net margin 16.2% 63 Earnings stabilityhigh72
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.8% 80 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage48
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +2.10% 20 Earnings growth (year over year) +29.30% 74 Average revenue growth (3 years) +7.64% 51 Financial strengthvery high83
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.03 83 Current ratio 3.21 78 Interest coverage 196.7 88 Dividendhigh73
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 2.7% 76 Payout ratio 43.1% 63 Consecutive dividend years 27 years 80 Market momentumstrong65
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +11.13% 69 Relative strength (6 months) +14.07% 72 1-year return +3.48% 49 Distance from 200-day average +4.54% 68 Risklow33
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 25.0% 29 Volatility (60 days) 39.6% 56 Beta (1 year) 0.18 14
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Kyowa Kirin is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Kyowa Kirin's P/E today is 20.3, below the median of its last 10 fiscal years (29.1; between 15.7 and 47.4 from 2016 to 2025). Kyowa Kirin's P/E (trailing 12 months): 16.6, −41% against the median of a group of 11 similar companies (28.4).
Compared with 11 similar companies
| Metric | Kyowa Kirin | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 16.6 | Low | |
| Forward P/E | 18.6 | Middle | |
| Operating margin | 21.8% | Middle | |
| ROE | 9.8% | Low | |
| Debt/equity | 0.03 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Kyowa Kirin. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥121.32B
Latest quarter · Q3 2026
Net income
¥21.06B
Latest quarter · Q3 2026
Quarterly net margin
17.4%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥1.35T
- P/E
- 16.6
- EPS
- ¥155.37
- Volume
- 1.14M
- Daily trading
- €25.52M
- Dividend yield
- 2.58%
How Kyowa Kirin is changing
All resultsRevenue grew 9.3% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 96% of net income
Revenue has grown for 6 fiscal years in a row
Returns
Kyowa Kirin returns with dividends
¥1,000 invested in Kyowa Kirin 5 years ago, on November 16, 2021, would be worth ¥797 today with dividends reinvested: −20.27% in total, −4.43% per year. On price alone it would be ¥716 (−28.36%).
| Period | Kyowa Kirin | Nikkei 225 | ¥1,000 becomes |
|---|---|---|---|
| 1 month | +11.04% | −6.39% | ¥1,110 |
| 6 months | +9.73% | −0.42% | ¥1,097 |
| Year to date | +2.91% | +21.48% | ¥1,029 |
| 1 year | +6.81% | +21.52% | ¥1,068 |
| 3 years | +16.45% | +82.95% | ¥1,164 |
| 5 years | −20.27% | +105.15% | ¥797 |
| 10 years | +86.27% | +242.35% | ¥1,863 |
Over the last 6 months it has done better than 39% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment
The chart in detail
Kyowa Kirin: technical analysis
Kyowa Kirin shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 38.2% below its all-time closing high (¥4,210.00, September 24, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 64
- Between 30 and 70
- vs 200-session average
- +5.16%
Support and resistance
Price areas where Kyowa Kirin has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance¥2,711.33+4.26%3 touches, last on July 29, 2026
- Resistance¥2,665.90+2.51%5 touches, last on November 5, 2026
- Last price¥2,600.50
- Support¥2,591.00−0.37%5 touches, last on July 14, 2026
- Support¥2,514.13−3.32%4 touches, last on August 18, 2026
- Support¥2,454.50−5.61%4 touches, last on August 4, 2026
Volatility and risk
Over the last year it has moved little with the Nikkei 225.
- Beta (1 year) vs Nikkei 225
- 0.18
- Volatility (60 sessions, annualised)
- 39.5%
- Largest fall in the last year
- −24.99%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Kyowa Kirin: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Kyowa Kirin has been February: +2.01% on average, positive in 19 years out of 37. The weakest has been December: −1.54% on average, positive in 12 years out of 36. November, the current month, has been positive in 19 years out of 36 (−0.41% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.76% | −1.22% | 16 of 36 |
| February | +2.01% | +0.60% | 19 of 37 |
| March | +0.33% | +1.00% | 21 of 37 |
| April | +1.77% | +3.33% | 26 of 37 |
| May | +0.22% | −0.30% | 17 of 37 |
| June | +0.61% | +0.52% | 20 of 37 |
| July | +0.97% | +2.62% | 21 of 37 |
| August | −0.45% | 0.00% | 18 of 37 |
| September | +0.06% | +0.42% | 19 of 37 |
| October | −0.22% | −0.63% | 17 of 37 |
| November | −0.41% | +0.76% | 19 of 36 |
| December | −1.54% | −2.20% | 12 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Kyowa Kirin and its competitors
Kyowa Kirin sells pharmaceuticals across Japan, the Americas, Europe and Asia, and in other international markets, and its development pipeline spans several therapeutic areas. Its marketed products include Ziftomenib, an oral menin inhibitor for adult relapsed or refractory acute myeloid leukemia with an NPM1 mutation, and Lumicef for palmoplantar pustulosis. Among its late-stage candidates are rocatinlimab for atopic dermatitis and prurigo nodularis, and infigratinib for achondroplasia, both in Phase III trials, alongside programs in ophthalmology, rare metabolic disorders and oncology.
- Headquarters
- Chiyoda, Japan
- Employees
- 5,161
- Founded
- 1949
- Chief executive
- Abdul Hafeez Mullick
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Kyowa Kirin4151 | $8.46B | 21.8% | 16.6 | +9.73% |
| Eisai4523 | $9.14B | 6.7% | 33.3 | +11.79% |
| CiplaCIPLA | $11.93B | 13.0% | 38.8 | −2.63% |
| Zhejiang NHU002001 | $12.3B | 33.8% | 10.9 | −21.99% |
| Sumitomo Pharma4506 | $5.69B | -0.4% | 19.2 | +18.08% |
| Zydus LifesciencesZYDUSLIFE | $12.59B | 17.2% | 28.4 | +17.82% |
Same industry or related industries, similar size. Compare Kyowa Kirin with its competitors · Full profile
